Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhengye Biotechnology HoldingZYBT -2.05%20 EV-to-FCF is 728.87 as of Aug. 25, 2026, which is 196% above its 10-year median of 246.26. GuruFocus rates ZYBT with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 559 Drug Manufacturers companies, Zhengye Biotechnology Holding ranks worse than 98.03% on this metric.
The historical rank and industry rank for Zhengye Biotechnology Holding's EV-to-FCF or its related term are showing as below:
ZYBT'
s EV-to-FCF Range Over the Past 10 Years
Min: 49.75 Med: 246.26 Max: 1079.6
Current: 728.87
During the past 5 years, the highest EV-to-FCF of Zhengye Biotechnology Holding was 1079.60. The lowest was 49.75. And the median was 246.26.
ZYBT's EV-to-FCF is ranked worse than 98.03% of 559
companies
in the Drug Manufacturers industry
Industry Median: 21.02
vs ZYBT: 728.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhengye Biotechnology Holding's PE Ratio (TTM) for today is calculated as:
Zhengye Biotechnology Holding's share price for today is $1.91.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhengye Biotechnology Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.208.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhengye Biotechnology Holding EV-to-FCF Related Terms
Zhengye Biotechnology Holding EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhengye Biotechnology Holding EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhengye Biotechnology Holding's EV-to-FCF falls into.
Zhengye Biotechnology Holding's current Enterprise Value is $102.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhengye Biotechnology Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhengye Biotechnology Holding (ZYBT) has a EV-to-FCF of 728.87 as of Aug. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhengye Biotechnology Holding and its competitors. This is 196% above median its historical median of 246.26. Over the past decade, Zhengye Biotechnology Holding's EV-to-FCF has ranged from 49.75 to 1,079.60. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #548 out of 559 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is Zhengye Biotechnology Holding's EV-to-FCF too high?
Zhengye Biotechnology Holding's current EV-to-FCF of 728.87 is 196% above median its 10-year median of 246.26. Over the past 10 years, this metric has ranged from a low of 49.75 to a high of 1,079.60. The Drug Manufacturers industry median EV-to-FCF is 21.02. Zhengye Biotechnology Holding's value of 728.87 is 3367.5% above this industry median. Based on the distribution chart, Zhengye Biotechnology Holding ranks #548 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's EV-to-FCF compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #548 out of 559 companies for EV-to-FCF. This places Zhengye Biotechnology Holding in the lower half of its industry. The industry median EV-to-FCF is 21.02. Zhengye Biotechnology Holding's value of 728.87 is 3367.5% above this benchmark. Historically, Zhengye Biotechnology Holding's own EV-to-FCF has ranged from 49.75 to 1,079.60 over the past decade. While the company's 10-year median is 246.26 vs. the industry median of 21.02, Zhengye Biotechnology Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhengye Biotechnology Holding's current EV-to-FCF of 728.87 is 3367.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhengye Biotechnology Holding and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhengye Biotechnology Holding's current EV-to-FCF is 728.87, which is 196% above median its own 10-year median of 246.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current EV-to-FCF of 728.87. The current EV-to-FCF is 728.87, which is 196% above median its 10-year median of 246.26 and 3367.5% above the Drug Manufacturers industry median of 21.02. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current EV-to-FCF is 728.87 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score
Get the complete analysis for ZYBT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYBT has been successfully added to your 
